Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14294078 | 0.85 | MTNR1A (0.55) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL30259913 | 0.85 | MTNR1A (0.55) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL5883325 | 0.84 | KMT2A (0.55) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL1567172 | 0.82 | KMT2A (0.53) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| Hydrochloric Acid SCHEMBL5883683 | 0.82 | KMT2A (0.53) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL4535798 | 0.81 | LIPG (0.52) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL1405700 | 0.81 | KMT2A (0.51) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL15831236 | 0.78 | KMT2A (0.53) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL8764868 | 0.77 | KMT2A (0.47) | HDAC3HDAC1HDAC2HDAC6HDAC4 | |
| SCHEMBL14269014 | 0.77 | LIPG (0.49) | HDAC3HDAC1HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | HDAC3 4325/4885HDAC1 3083/4885HDAC2 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.